Insilico Medicine announced on Apr. 10 that it will hold the Pharma.AI Spring Kickoff 2026 webinar at 10:00 AM Eastern Time on April 14. The event is part of the company's ongoing efforts to explore advancements in artificial intelligence for drug discovery and scientific research.
The upcoming season of the Pharma.AI webinar series aims to showcase how foundation models and specialized AI tools are shaping new opportunities in pharmaceutical research, including drug design and decision-making processes. Insilico Medicine said the event will highlight developments across its Pharma.AI ecosystem, including updates to core modules such as PandaOmics, Generative Biologics, Chemistry42, and the MMAI Gym for Science.
The MMAI Gym for Science is a training framework introduced by Insilico in January that leverages over a thousand drug research benchmarks and about 120 billion tokens of data to enhance performance of foundation models on specialized tasks. According to Insilico Medicine, “we demonstrate that MMAI-trained foundation models achieved up to 10X performance gains on key drug discovery benchmarks compared to general-purpose foundation models, which fell short on approximately 75–95% of tasks.” In March, Insilico collaborated with Liquid AI to deliver LFM2-2.6B-MMAI (v0.2.1), described as a lightweight model delivering state-of-the-art results across several key tasks.
Attendees will learn about supervised fine-tuning (SFT) and reinforcement fine-tuning (RFT) systems designed to improve causal large language model performance in real-world drug discovery scenarios.
The company also outlined upgrades to its PandaOmics platform—including integration of single-cell datasets—and new features like PandaClaw for multi-omics analysis using natural-language commands. Chemistry42 now offers multitarget molecule generation support and enhanced visualization tools; Nach01-MMAI further enables molecule generation through advanced modeling techniques. Updates in Generative Biologics include workflows supporting cyclic peptide design and improvements in optimizing biologic candidates.
Pharma.AI is described by Insilico Medicine as an end-to-end platform integrating target discovery, generative chemistry, biologics design, and predictive clinical modeling into one workflow for pharmaceutical development.
